tjh-v38i2

Turk J Hematol 2021;38:126-137
Peng Y. et al: Allo-HSCT in Extranodal Lymphoma
Time from
diagnosis to
allo-HSCT
Disease status at
transplantation
Conditioning
regimens
Regimen
intensity
Source of
hematopoietic
stem cells
Donor
matching
PFS
OS
Rate of
relapse
Result
GVHD
Unknown Recurrence CY + TBI MC BM
Unknown PD CY + TBI MC PBSC
Matched-related
donor
Matched-related
donor
7 months PD CY + TBI MC CB CB 0
4 months, 9
months
Unknown
Relapsed
locally
Non-CR MC/RIC MC/RIC PBSC Relapsed Died
Relapse and
CR 2 : 3 (60%),
refractory: 1
(20%), relapse: 1
(20%)
CA/CY/TBI, TBI/
CY, CA/CY/TBI,
CY/TBI, CA/
CY/TBI
MC: 5
(100%)
Unknown Relapse CY + TBI MC PBSC
6 months CR
Unknown
3 months, 5
months
PR
PR-CR, PR
Fludarabine
+ melphalan
+ TBI
BEAM/Cam
(alemtuzumab)
IBUCY, FLAG +
BUCY
RIC
MC
MC
BM: 3 (60%),
CB: 2 (40%)
BM
PBSC
PBSC
Matched-related
donor: 2 (40%),
CB: 2 (40%),
unknown: 1
(20%)
Haploidenticalrelated
donor
Matchedunrelated
donor
Haploidenticalrelated
donor
Matched-related
donor: 2 (100%)
60%
(3-year
PFS)
60%
(3-year
OS)
0
0
Relapsed
locally
Relapsed
0
0
CR and alive
for 4 years
CR and alive
for 2 years
CR and
alive for 18
months
CR and alive
for median
follow-up
time of 1911
days (range:
888-2617
days)
CR and alive
for more
than 1 year
Died
CR and alive
for 1400
days
CR and
alive for 66
months and
50 months,
respectively
cGVHD:
skin and
liver
cGVHD:
oral
mucosa
and liver
aGVHD:
skin (grade
3), cGVHD:
skin and
pericardial
effusion
aGVHD:
skin
aGVHD:
2 (40%),
cGVHD: 3
(60%)
aGVHD
(grade II)
of skin,
cGVHD of
liver
No aGVHD
or cGVHD
aGVHD
(grade II),
no cGVHD
No aGVHD
or cGVHD
137